[
    [
        {
            "time": "2018-01-03",
            "original_text": "Cramer's lightning round: Mercadolibre is even better than eBay was",
            "features": {
                "keywords": [
                    "Mercadolibre",
                    "eBay",
                    "better"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "e-commerce"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Cramer's lightning round: Mercadolibre is even better than eBay was",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Galapagos Reports Topline Data From Osteoarthritis Study",
            "features": {
                "keywords": [
                    "Galapagos",
                    "Osteoarthritis",
                    "Topline",
                    "Data"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Galapagos Reports Topline Data From Osteoarthritis Study",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Understanding AbbVie’s Positive Upadacitinib Data for Atopic Dermatitis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Upadacitinib",
                    "Atopic Dermatitis",
                    "Positive Data"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Understanding AbbVie’s Positive Upadacitinib Data for Atopic Dermatitis",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "US STOCKS-Wall St new year rally pauses as healthcare, bank stocks weigh",
            "features": {
                "keywords": [
                    "US Stocks",
                    "Wall St",
                    "rally",
                    "healthcare",
                    "bank stocks"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "US STOCKS-Wall St new year rally pauses as healthcare, bank stocks weigh",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Upadacitinib",
                    "Rheumatoid Arthritis",
                    "Strong Data"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Upadacitinib",
                    "Breakthrough Therapy",
                    "FDA",
                    "Atopic Dermatitis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "What Upadacitinib Did for AbbVie in 2017",
            "features": {
                "keywords": [
                    "Upadacitinib",
                    "AbbVie",
                    "2017"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What Upadacitinib Did for AbbVie in 2017",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "This Is Expected to Boost AbbVie’s Growth Prospects",
            "features": {
                "keywords": [
                    "Boost",
                    "Growth Prospects",
                    "AbbVie"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "This Is Expected to Boost AbbVie’s Growth Prospects",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Why Humira Is Still a Solid Growth Driver for AbbVie in 2018",
            "features": {
                "keywords": [
                    "Humira",
                    "Solid Growth Driver",
                    "AbbVie",
                    "2018"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why Humira Is Still a Solid Growth Driver for AbbVie in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "How Increasing Biologic Penetration Could Boost AbbVie’s Revenues",
            "features": {
                "keywords": [
                    "Increasing Biologic Penetration",
                    "Boost",
                    "Revenues",
                    "AbbVie"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Increasing Biologic Penetration Could Boost AbbVie’s Revenues",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]